Servier pays $70M to polish Black Diamond's deprioritized solid tumor prospect
Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones.
Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones.
